287 related articles for article (PubMed ID: 12181740)
21. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of peripheral benzodiazepine receptor ligand-induced apoptosis and cell cycle arrest of esophageal cancer cells by simultaneous inhibition of MAPK/ERK kinase.
Sutter AP; Maaser K; Gerst B; Krahn A; Zeitz M; Scherübl H
Biochem Pharmacol; 2004 May; 67(9):1701-10. PubMed ID: 15081869
[TBL] [Abstract][Full Text] [Related]
23. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade.
Kim PN; Jonasch E; Mosterman BC; Mier JW; Janssen RA
Cell Growth Differ; 2001 Nov; 12(11):543-50. PubMed ID: 11714635
[TBL] [Abstract][Full Text] [Related]
24. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Gysin S; Lee SH; Dean NM; McMahon M
Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
[TBL] [Abstract][Full Text] [Related]
26. Rac-PAK signaling stimulates extracellular signal-regulated kinase (ERK) activation by regulating formation of MEK1-ERK complexes.
Eblen ST; Slack JK; Weber MJ; Catling AD
Mol Cell Biol; 2002 Sep; 22(17):6023-33. PubMed ID: 12167697
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
[TBL] [Abstract][Full Text] [Related]
28. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
29. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis.
Wu J; Wong WW; Khosravi F; Minden MD; Penn LZ
Cancer Res; 2004 Sep; 64(18):6461-8. PubMed ID: 15374955
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites.
Rice PL; Goldberg RJ; Ray EC; Driggers LJ; Ahnen DJ
Cancer Res; 2001 Feb; 61(4):1541-7. PubMed ID: 11245463
[TBL] [Abstract][Full Text] [Related]
31. MEK1 and Erk1/2 kinases as targets for the modulation of radiation responses.
Belka C; Knippers P; Rudner J; Faltin H; Bamberg M; Budach W
Anticancer Res; 2000; 20(5A):3243-9. PubMed ID: 11062749
[TBL] [Abstract][Full Text] [Related]
32. BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma.
Breunig C; Mueller BJ; Umansky L; Wahl K; Hoffmann K; Lehner F; Manns MP; Bantel H; Falk CS
Clin Cancer Res; 2014 May; 20(9):2410-23. PubMed ID: 24573550
[TBL] [Abstract][Full Text] [Related]
33. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
[TBL] [Abstract][Full Text] [Related]
34. UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway.
Facchinetti MM; De Siervi A; Toskos D; Senderowicz AM
Cancer Res; 2004 May; 64(10):3629-37. PubMed ID: 15150122
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2.
Yip-Schneider MT; Lin A; Marshall MS
Biochem Biophys Res Commun; 2001 Feb; 280(4):992-7. PubMed ID: 11162624
[TBL] [Abstract][Full Text] [Related]
36. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
[TBL] [Abstract][Full Text] [Related]
37. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.
Yip-Schneider MT; Schmidt CM
Pancreas; 2003 Nov; 27(4):337-44. PubMed ID: 14576498
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK.
Allan LA; Morrice N; Brady S; Magee G; Pathak S; Clarke PR
Nat Cell Biol; 2003 Jul; 5(7):647-54. PubMed ID: 12792650
[TBL] [Abstract][Full Text] [Related]
39. The MEK1-ERK map kinase pathway and the PI 3-kinase-Akt pathway independently mediate anti-apoptotic signals in HepG2 liver cancer cells.
Mitsui H; Takuwa N; Maruyama T; Maekawa H; Hirayama M; Sawatari T; Hashimoto N; Takuwa Y; Kimura S
Int J Cancer; 2001 Apr; 92(1):55-62. PubMed ID: 11279606
[TBL] [Abstract][Full Text] [Related]
40. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
